目的 了解2019年苏州九龙医院信迪利单抗的使用合理性。方法 对苏州九龙医院2019年1月-2019年12月使用过信迪利单抗的24例患者，63次用药情况进行回顾性分析，按原发肿瘤进行分类，参考说明书及相关文献信息对患者治疗情况进行统计分析，评价其使用合理性。结果 信迪利单抗主要用于肺恶性肿瘤和结直肠恶性肿瘤，构成比分别为25.0%、16.7%；63次治疗中，7次为单药使用信迪利单抗，56次为联合用药；用药疗程中有7例无故中断信迪利单抗的继续治疗；2次用量为单次100 mg，2次用量为200 mg分2次使用（间隔3~5 d）。用药不合理主要表现为超适应症用药（100.0%）、联合用药不合理（3.2%）、用药疗程不合理（29.2%）和用法用量不合理（6.3%）4个方面。结论 苏州九龙医院信迪利单抗的超说明书应用情况普遍存在，鉴于PD-1类药物特殊的抗肿瘤机制，随着更多的相关临床研究加速开展，信迪利单抗将在肿瘤治疗中发挥更大的作用。

Objective To investigate the rationality of sintilimab in Suzhou Kowloon Hospital in 2019. Methods The application of sintilimab for 24 patients (63 times) were retrospectively analyzed and evaluated in Suzhou Kowloon Hospital from January 2019 to December 2019. The reasonable use of sintilimab was evaluated according to the classification of primary tumors, drug instructions, and relevant literature information. Results Sindelizumab was mainly used in lung and colorectal malignancies, accounted for 25.0% and 16.7%. In 63 times of treatment, zimidazumab was used as a monotherapy with 7 times, while zimidazumab was used as drug combination with 56 times. In the course of treatment, 7 cases were interrupted without reason. There was twice with dosage of 100 mg in a single dose, while twice with dosage of 200 mg in twice dose (interval of 3-5 d). The irrational use of sintilimab was mainly manifested in the following four aspects:off-label use (100.0%), irrational combination use (3.2%), irrational medication course (29.2%), and unreasonable usage and dosage (6.3%). Conclusion The off-label use of sintilimab is common in Suzhou Kowloon Hospital. In view of the special anti-tumor mechanism of PD-1, with the development of more relevant clinical research, sintilimab will play a greater role in tumor treatment.

R969.3